- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06416046
Efficacy of Photobiomodulation in the Treatment and Relief of Pain in Recurrent Aphthous Stomatitis
Efficacy of Photobiomodulation in the Treatment and Relief of Pain in Recurrent Aphthous Stomatitis: a Randomized, Triple-blind, Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Manoela Martins, PhD
- Phone Number: 555133085011
- Email: manomartins@gmail.com
Study Contact Backup
- Name: Liliana Braun
- Phone Number: 5551996664438
- Email: lili.wolfb@hotmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients over the age of 18
- Patients presenting at least one painful mouth ulcer (minor ulcer), located on the tongue, jugal mucosa or labial mucosa, starting on the same day or the day before.
Exclusion Criteria:
- Patients who have already undergone other treatment for RAS;
- Patients with asymptomatic ulcers;
- Patient must not be undergoing or have undergone any treatment for RAS;
- Patients with any systemic condition related to RAS - e.g. Behcet's Syndrome, Periodic Fever Syndrome, Pharyngitis and Cervical Adenitis, HIV infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intraoral photobiomodulation (PBM)
A gallium-aluminum arsenide diode laser (Gemini® manufactured by Azena Medical, LLC, distributed by Ultradent Products, Inc.) with double wavelength 810 + 980 nm. The equipment will be programmed with 0,3W of power. The application of PBM will be carried out for at least 03 alternate days within 01 week by a trained professional. Patients who still have an ulcerated lesion on the 7th day will be assessed every 2 days until complete healing. During each irradiation, the applicator and patients will wear specific protective goggles and the instruments will be disinfected with an antiseptic solution (Chlorhexidine 2%). Points of application: Equidistant points (0.5cm) along the length of the lesion and in contact with the lesion. |
Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis.
A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
|
Placebo Comparator: Placebo
The application of placebo will be carried out for at least 03 alternate days within 01 week (3x within 07 days) by a trained professional.
Patients who still have an ulcerated lesion on the 7th day will be assessed every 2 days until complete healing.
The device will not be activated and the applicator and patients will wear specific protective goggles and the instruments will be disinfected with antiseptic solution (Chlorhexidine 2%).
|
Examination and follow-up until the lesion heals spontaneously.
The laser will not be activated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain assessment
Time Frame: 1 week
|
Pain will be assessed at all appointments using the Visual Analog Scale (VAS), which will be represented by a 10 cm straight line, where 0 corresponds to the best situation and 10 to the worst situation.
The research subjects will be instructed by the evaluator to mark a point on the 10 cm line.
|
1 week
|
Assessment of ulcer size
Time Frame: 1 week
|
Ulcer size will be assessed at every appointment using the tip of a millimeter-sized periodontal probe.
|
1 week
|
Functional assessment
Time Frame: 1 week
|
The functional assessment will be carried out at all appointments, evaluating the patient's subjective experience of difficulty in eating, drinking and brushing their teeth due to the presence of RAS.
The answers will be scored from 0 (no difficulty) to 4 (a lot of difficulty) according to the questionnaire given to the patients
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time measurement
Time Frame: 1 week
|
The time of all the sessions carried out will be timed with the aid of a stopwatch, starting at the beginning of the device's activation until its deactivation.
The time in seconds will be recorded on the daily evaluation form.
|
1 week
|
Saliva collection
Time Frame: 1 week
|
Saliva samples will be collected from participants at two clinical assessment points.
Patients must abstain from eating or drinking for 30 minutes prior.
Saliva is collected unstimulated, with patients seated, eyes open, head slightly tilted down, and refraining from speaking, swallowing, or mouth opening for 5 minutes.
Samples are collected in sterile Falcon tubes, immediately placed on ice, and stored at -80°C for later inflammatory marker analysis.
Samples are stored in HCPA's Biobank per regulations and analyzed at CPE, then discarded post-analysis.
|
1 week
|
Collaborators and Investigators
Investigators
- Study Director: Manoela Martins, PhD, Federal University of Rio Grande do Sul
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMB and RAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomatitis, Aphthous
-
Mashhad University of Medical SciencesCompletedRecurrent Aphthous StomatitisIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesCompletedRecurrent Aphthous Stomatitis | Recurrent Aphthous UlcerIran, Islamic Republic of
-
British University In EgyptNot yet recruitingTreatment Compliance | Aphthous Stomatitis (Major) (Minor)Egypt
-
Kafrelsheikh UniversityCompletedAntioxidative Stress | Aphthous Stomatitis, RecurrentEgypt
-
Universitat Internacional de CatalunyaCompletedAphthous StomatitisSpain
-
Cairo UniversityCompleted
-
Meir Medical CenterTerminatedRecurrent Aphthous StomatitisIsrael
-
Peking UniversityCompletedRecurrent Aphthous Stomatitis
-
Soroka University Medical CenterCompletedRecurrent Aphthous StomatitisIsrael
Clinical Trials on Gemini laser
-
Federal University of Rio Grande do SulHospital A.C. CamargoRecruitingChildhood Cancer | Chemotherapeutic Toxicity | Oral MucositisBrazil
-
Neovasc Inc.CompletedAngioplastyUnited States, Canada, Netherlands
-
Abbott Medical DevicesCompleted
-
Omega OphthalmicsCompleted
-
University of Maryland, BaltimoreAstellas Pharma IncTerminated
-
Mansoura UniversityUnknownApical Root Resorption | Labial Alveolar Bone ThicknessEgypt
-
Omega OphthalmicsCompleted
-
Hologic, Inc.Completed
-
Coopervision, Inc.CompletedMyopiaUnited States
-
Jordan University of Science and TechnologyCompleted